Percentage of Secondary Prevention Patients Treated to Their LDL-C Targets

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2009 by AstraZeneca.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00536965
First received: September 27, 2007
Last updated: January 21, 2009
Last verified: January 2009
  Purpose

A cholesterol/lipid profile screening project of high risk patients with hyperlipidaemia (secondary prevention) who already receive cholesterol-lowering therapy. Lipid profile and rate of patients who are treated to target (which is <100mg/dl for patients with high risk and <70mg/dl for patients at very high risk) are screened (office-based specialists). The doctors therapy decisions after the screening and possible reasons for these decisions will be documented. Our aim is to evaluate dosing habits, to evaluate how many patients are treated to their LDL-C target and to underline the importance of treating patients to their cholesterol targets.


Condition
Hyperlipidemias
Atherosclerosis
Coronary Heart Disease
Carotid Stenosis
Peripheral Vascular Diseases
Diabetes Mellitus

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Non-Interventional Study Investigating How Effective Secondary Prevention Patients Are Treated to Their LDL-C Targets

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Estimated Enrollment: 2400
Study Start Date: September 2007
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Secondary prevention patients with hyperlipidemia and atherosclerosis (coronary heart disease, carotid stenosis, PVD, etc.) and/or diabetes who already receive cholesterol-lowering therapy

Exclusion Criteria:

  • Patients who do not receive cholesterol-lowering therapy
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00536965

Locations
Austria
Research Site
Vienna, Austria
Sponsors and Collaborators
AstraZeneca
Investigators
Study Chair: Josef Patsch, MD Chair of the Austrian Atheroslerosis Society
Study Chair: Bernhard Foger, MD Co-Chair of the Austrian Atheroslerosis Society
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00536965     History of Changes
Other Study ID Numbers: NIS-CAT-CRE-2007/1
Study First Received: September 27, 2007
Last Updated: January 21, 2009
Health Authority: Not required for this study:

Keywords provided by AstraZeneca:
Hyperlipidemia
Need-to-treat
NIS
Secondary prevention patients with hyperlipidemia and atherosclerosis (coronary heart disease, carotid stenosis, PVD, etc.) and/or diabetes

Additional relevant MeSH terms:
Atherosclerosis
Carotid Stenosis
Constriction, Pathologic
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Diabetes Mellitus
Heart Diseases
Hyperlipidemias
Vascular Diseases
Peripheral Vascular Diseases
Peripheral Arterial Disease
Arteriosclerosis
Arterial Occlusive Diseases
Cardiovascular Diseases
Carotid Artery Diseases
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Pathological Conditions, Anatomical
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Dyslipidemias
Lipid Metabolism Disorders

ClinicalTrials.gov processed this record on April 15, 2014